Reuters logo
BRIEF-Biogen says Spinraza approved in EU as first treatment for SMA
June 1, 2017 / 11:35 AM / in 5 months

BRIEF-Biogen says Spinraza approved in EU as first treatment for SMA

June 1 (Reuters) - Biogen Inc:

* Spinraza (nusinersen) approved in the European Union as first treatment for spinal muscular atrophy

* Biogen - ‍approval was also supported by open-label data in pre-symptomatic and symptomatic individuals with, or likely to develop, types 1, 2 and 3 SMA​

* Biogen Inc - ‍timing of Spinraza availability in eu will vary by country, per local reimbursement and access pathways​

* Biogen Inc - ‍Biogen has been working with health systems and government agencies across EU to help patients secure access to Spinraza​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below